Galleri is a multi-cancer early detection (MCED) or 'liquid biopsy' test that Grail says can spot signs of up to 50 different ...

A wireless sensor the size of a paperclip, Abbott's CardioMEMS HF, can be used routinely by the NHS to monitor patients with ...

Phase 2 results in advanced pancreatic cancer were presented at last year's ASCO cancer congress, and the live ...

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits, fuelled ...

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed ...

The confluence of China’s rapidly rising biotech prowess and US policy decisions that hamper the industry is a cause for ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

Looking ahead to 2026, Doustdar said Novo Nordisk had high expectations for the potential launches of new incretin ...

When it comes to developing new cancer treatments, too often teams are focused on finding the treatment that most effectively kills tumours. But that’s only part of the goal, argues Immuneering CEO ...

"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

ICH E6 (R3) introduces a dedicated section on data governance, reflecting the increasing complexity of data sources and ...